Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson's Disease Psychosis: Systematic Review and Network Meta-Analysis

被引:9
|
作者
Yunusa, Ismaeel [1 ,4 ]
Rashid, Nazia [2 ]
Seyedin, Roxanna [3 ]
Paratane, Deepika [3 ]
Rajagopalan, Krithika [3 ]
机构
[1] Univ South Carolina, Coll Pharm, Columbia, SC USA
[2] Acadia Pharmaceut Inc, San Diego, CA USA
[3] Anlitiks Inc, Windermere, FL USA
[4] Univ South Carolina, Coll Pharm, Dept Clin Pharm & OutcomesSciences, 715 Sumter St, Columbia, SC 29208 USA
关键词
Parkinson disease; psychiatry; neurology; mental health; geriatrics; DRUG-INDUCED PSYCHOSIS; DOUBLE-BLIND; CLOZAPINE; QUETIAPINE; OLANZAPINE; INCONSISTENCY; HALLUCINATIONS; CONSISTENCY; GENERATION; SYMPTOMS;
D O I
10.1177/08919887231154933
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background The current comparative efficacy, safety, and acceptability of atypical antipsychotics (AAPs) in treating Parkinson's Disease Psychosis (PDP) are not entirely understood. Objective To evaluate comparative efficacy, safety, and acceptability of AAPs in patients with PDP. Methods We conducted a systematic review and a network meta-analysis to compare the efficacy, safety, and acceptability of pimavanserin, quetiapine, olanzapine, clozapine, ziprasidone, and risperidone. We estimated relative standardized mean differences (SMDs) for continuous outcomes and odds ratios (OR) for binary outcomes, with their respective 95% confidence intervals (CIs). Results We included 19 unique studies evaluating AAPs in a total of 1,242 persons with PDP. Based on Clinical Global Impression Scale for Severity, pimavanserin (SMD, -4.81; 95% CI, -5.39, -4.24) and clozapine (SMD, -4.25; 95% CI, -5.24, -3.26) significantly improved symptoms compared with placebo. Also, compared to placebo, pimavanserin (OR, 1.16; 95% CI, 1.07, 1.24) significantly improved psychotic symptoms based on Scale for Assessment of Positive Symptoms for Parkinson's Disease Psychosis/Hallucinations and Delusions scores. In comparison to placebo, clozapine (SMD, -0.69; 95% CI, -1.35, -0.02), pimavanserin (SMD, -0.01; 95% CI, -0.56, 0.53), and quetiapine (SMD, 0.00; 95% CI, -0.68, 0.69) did not impair motor function per Unified Parkinson's Disease Rating scale. Based on Mini-Mental State Examination scale, quetiapine (SMD, 0.60; 95% CI, 0.07, 1.14) significantly impaired cognition compared to placebo. Conclusions In patients with PDP, pimavanserin and clozapine demonstrated significant improvement in psychosis without affecting motor function. With quetiapine being associated with a significant decline in cognition and despite not impairing motor function, our findings suggest that it should be avoided in patients with PDP and reduced cognitive abilities.
引用
收藏
页码:417 / 432
页数:16
相关论文
共 50 条
  • [1] Efficacy and safety of atypical antipsychotics for psychosis in Parkinson's disease: A systematic review and Bayesian network meta-analysis
    Iketani, Ryo
    Furushima, Daisuke
    Imai, Shinobu
    Yamada, Hiroshi
    [J]. PARKINSONISM & RELATED DISORDERS, 2020, 78 : 82 - 90
  • [2] Atypical antipsychotics for Parkinson's disease psychosis: a systematic review and meta-analysis
    Zhang, Han
    Wang, Limin
    Fan, Yafei
    Yang, Lianhong
    Wen, Xiaojun
    Liu, Yunyun
    Liu, Zhonglin
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2019, 15 : 2137 - 2149
  • [3] Comparative Utility of Atypical Antipsychotics for the Treatment of Psychosis in Parkinson's Disease: A Systematic Review and Bayesian Network Meta-analysis
    Iketani, Ryo
    Kawasaki, Yohei
    Yamada, Hiroshi
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2017, 40 (11) : 1976 - 1982
  • [4] Acceptability of Atypical Antipsychotics in Treating Parkinson's Disease Psychosis: A Systematic Literature Review
    Yunusa, I.
    Rashid, N.
    Seyedin, R.
    Mahadik, B.
    Rajagopalan, K.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2020, 70 : S93 - S93
  • [6] Antipsychotics for the management of psychosis in Parkinson's disease: systematic review and meta-analysis
    Jethwa, Ketan Dipak
    Onalaja, Oluwademilade A.
    [J]. BJPSYCH OPEN, 2015, 1 (01): : 27 - 33
  • [7] Comparative efficacy and acceptability of drug treatments for Parkinson's disease with depression: A systematic review with network meta-analysis
    Wang, Xiao-Le
    Feng, Si-Tong
    Wang, Ya-Ting
    Chen, Bin
    Wang, Zhen-Zhen
    Chen, Nai-Hong
    Zhang, Yi
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2022, 927
  • [8] Second-generation antipsychotics for Parkinson's disease psychosis: A systematic review and network meta-analysis
    Srisurapanont, Manit
    Suradom, Chawisa
    Suttajit, Sirijit
    Kongsaengdao, Subsai
    Maneeton, Benchalak
    [J]. GENERAL HOSPITAL PSYCHIATRY, 2024, 87 : 124 - 133
  • [9] Comparative Efficacy and Acceptability of Antidepressants in Parkinson's Disease: A Network Meta-Analysis
    Liu, Jinling
    Dong, Jiangchuan
    Wang, Lei
    Su, Ying
    Yan, Peng
    Sun, Shenggang
    [J]. PLOS ONE, 2013, 8 (10):
  • [10] EFFICACY AND SAFETY ORTOLERABILITY OF ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF BIPOLAR DEPRESSION: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
    Hagi, K.
    Nosaka, T.
    Pikalov, A.
    Loebel, A.
    Correll, C.
    Hopwood, M.
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 : 145 - 145